Company intelligence / Profile preview

Amniotic

Lund, Sweden

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Amniotics was a Swedish biotechnology company specializing in the development of cell therapies derived from amniotic fluid. The company utilized a proprietary collection and selection process to harvest neonatal mesenchymal stem cells (MSCs) from full-term deliveries, which are characterized by higher proliferation and lower immunogenicity compared to adult-derived cells. Their lead candidate, PulmoStem, was being evaluated for inflammatory and fibrotic lung diseases, including ARDS and COVID-19. Despite promising early-stage clinical progress, the company faced significant financial challenges and filed for bankruptcy in June 2024.

Therapeutic areas: CardiovascularDermatologyNephrologyPulmonology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Amniotic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amniotic.

Explore the full profile